Aldeyra's dry eye drug gets a re­jec­tion from the FDA

The FDA hand­ed down a com­plete re­sponse let­ter to Aldeyra Ther­a­peu­tics for its dry eye dis­ease drug re­prox­alap, fol­low­ing months of spec­u­la­tion about whether the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER